FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100129802> ?p ?o ?g. }

• W2100129802 endingPage "587" @default.
• W2100129802 startingPage "579" @default.
• W2100129802 abstract "Abstract Objective To evaluate the efficacy of dose escalation of Octreotide-long-acting repeatable (LAR) up to 40 mg/month we studied 56 newly diagnosed patients with acromegaly (24 women, 32 men; age 20–82 years). Design Analytical, observational, open and prospective. Methods Three months after LAR treatment beginning with a dose of 20 mg /q28d (every 28 days), 24 patients maintained the same dose (Group A), while 32 required a dose of 30 mg/q28d (Group B). The dose was further increased to 40 mg/q28d in 17 out of the 32 patients of Group B for another 12 months (Group C). Results After 24 months, serum GH and IGF-I levels decreased by 93.1±8.6% (95% confidence limit (CL) 90.8–95.4%) and 62.7±13.4% (95% CL 59.1–66.3%) respectively. Control of GH and IGF-I levels was achieved in 45 patients (80.3%). Tumor shrinkage after 12 months was 49.8±23%; the relative tumor shrinkage during the second 12 months of treatment was 35.3±13.1% and overall tumor volume was 68.1±16.5% (95% CL 63.7–72.5%). Glucose tolerance impaired in eight patients (14.3%): four in Group A and four in Group C (16.7% vs 36.4%, P =0.39). The final dose was predicted by the patient's age at diagnosis ( t =−2.2; P =0.032) and baseline tumor volume ( t =2.1; P =0.043). Conclusion An increase of the LAR dose up to 40 mg/q28d in patients resistant to 30 mg/q28d is followed by greater suppression of GH and IGF-I levels and tumor shrinkage without further significant impairment of glucose tolerance when compared with lower doses. These results suggest that a new dosage schedule of 40 mg every 28 days is applied in patients with acromegaly mostly of young age and with bigger tumors who are likely to be poorly responsive to standard doses of Octreotide-LAR." @default.
• W2100129802 created "2016-06-24" @default.
• W2100129802 creator A5003544129 @default.
• W2100129802 creator A5015141404 @default.
• W2100129802 creator A5036471704 @default.
• W2100129802 creator A5055828753 @default.
• W2100129802 creator A5063936702 @default.
• W2100129802 creator A5077499862 @default.
• W2100129802 date "2007-11-01" @default.
• W2100129802 modified "2023-10-02" @default.
• W2100129802 title "Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly" @default.
• W2100129802 cites W1967226362 @default.
• W2100129802 cites W1975874471 @default.
• W2100129802 cites W1983367273 @default.
• W2100129802 cites W1988701052 @default.
• W2100129802 cites W1989662643 @default.
• W2100129802 cites W1993733299 @default.
• W2100129802 cites W2002070825 @default.
• W2100129802 cites W2028425454 @default.
• W2100129802 cites W2040054585 @default.
• W2100129802 cites W2040743647 @default.
• W2100129802 cites W2045942594 @default.
• W2100129802 cites W2075577428 @default.
• W2100129802 cites W2088201477 @default.
• W2100129802 cites W2118341413 @default.
• W2100129802 cites W2119094244 @default.
• W2100129802 cites W2120902410 @default.
• W2100129802 cites W2123416598 @default.
• W2100129802 cites W2140572454 @default.
• W2100129802 cites W2143791513 @default.
• W2100129802 cites W2149789254 @default.
• W2100129802 cites W2157482119 @default.
• W2100129802 cites W2160234571 @default.
• W2100129802 cites W2160989555 @default.
• W2100129802 cites W2161555684 @default.
• W2100129802 cites W2167999612 @default.
• W2100129802 cites W2169376102 @default.
• W2100129802 cites W4205321574 @default.
• W2100129802 cites W4239713360 @default.
• W2100129802 cites W4244756344 @default.
• W2100129802 cites W4245963876 @default.
• W2100129802 cites W4256608891 @default.
• W2100129802 doi "https://doi.org/10.1530/eje-07-0383" @default.
• W2100129802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17984237" @default.
• W2100129802 hasPublicationYear "2007" @default.
• W2100129802 type Work @default.
• W2100129802 sameAs 2100129802 @default.
• W2100129802 citedByCount "75" @default.
• W2100129802 countsByYear W21001298022012 @default.
• W2100129802 countsByYear W21001298022013 @default.
• W2100129802 countsByYear W21001298022014 @default.
• W2100129802 countsByYear W21001298022015 @default.
• W2100129802 countsByYear W21001298022016 @default.
• W2100129802 countsByYear W21001298022017 @default.
• W2100129802 countsByYear W21001298022018 @default.
• W2100129802 countsByYear W21001298022019 @default.
• W2100129802 countsByYear W21001298022020 @default.
• W2100129802 countsByYear W21001298022021 @default.
• W2100129802 countsByYear W21001298022022 @default.
• W2100129802 countsByYear W21001298022023 @default.
• W2100129802 crossrefType "journal-article" @default.
• W2100129802 hasAuthorship W2100129802A5003544129 @default.
• W2100129802 hasAuthorship W2100129802A5015141404 @default.
• W2100129802 hasAuthorship W2100129802A5036471704 @default.
• W2100129802 hasAuthorship W2100129802A5055828753 @default.
• W2100129802 hasAuthorship W2100129802A5063936702 @default.
• W2100129802 hasAuthorship W2100129802A5077499862 @default.
• W2100129802 hasBestOaLocation W21001298021 @default.
• W2100129802 hasConcept C126322002 @default.
• W2100129802 hasConcept C126894567 @default.
• W2100129802 hasConcept C134018914 @default.
• W2100129802 hasConcept C2776297358 @default.
• W2100129802 hasConcept C2777433750 @default.
• W2100129802 hasConcept C2781025020 @default.
• W2100129802 hasConcept C2984496839 @default.
• W2100129802 hasConcept C44249647 @default.
• W2100129802 hasConcept C71315377 @default.
• W2100129802 hasConcept C71924100 @default.
• W2100129802 hasConcept C90924648 @default.
• W2100129802 hasConceptScore W2100129802C126322002 @default.
• W2100129802 hasConceptScore W2100129802C126894567 @default.
• W2100129802 hasConceptScore W2100129802C134018914 @default.
• W2100129802 hasConceptScore W2100129802C2776297358 @default.
• W2100129802 hasConceptScore W2100129802C2777433750 @default.
• W2100129802 hasConceptScore W2100129802C2781025020 @default.
• W2100129802 hasConceptScore W2100129802C2984496839 @default.
• W2100129802 hasConceptScore W2100129802C44249647 @default.
• W2100129802 hasConceptScore W2100129802C71315377 @default.
• W2100129802 hasConceptScore W2100129802C71924100 @default.
• W2100129802 hasConceptScore W2100129802C90924648 @default.
• W2100129802 hasIssue "5" @default.
• W2100129802 hasLocation W21001298021 @default.
• W2100129802 hasLocation W21001298022 @default.
• W2100129802 hasOpenAccess W2100129802 @default.
• W2100129802 hasPrimaryLocation W21001298021 @default.
• W2100129802 hasRelatedWork W1585166224 @default.
• W2100129802 hasRelatedWork W1982345662 @default.
• W2100129802 hasRelatedWork W2006011837 @default.

• next